Obesity-associated insulin resistance is correlated to adipose tissue vascular endothelial growth factors and metalloproteinase levels

BMC Physiology

Volumn 12, Issue 1, 2012, Pages

  Tinahones, Francisco José ^a,b   Coín Aragüez, Leticia ^a,b   Mayas, Maria Dolores ^a,b   Garcia Fuentes, Eduardo ^a,b   Hurtado Del Pozo, Carmen ^c   Vendrell, Joan ^d   Cardona, Fernando ^a,b   Calvo, Rosa Maria ^c   Obregon, Maria Jesus ^c   El Bekay, Rajaa ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Insulin Resistance; Obesity; Omentum Adipose Tissue; Subcutaneous Adipose Tissue; Vascular Endothelial Growth Factor and Metalloproteinase

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; METALLOPROTEINASE; VASCULOTROPIN A;

ADIPOSE TISSUE; ANGIOGENESIS; ARTICLE; GENE EXPRESSION; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLISM; MORBID OBESITY; OBESITY; OMENTUM; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBCUTANEOUS FAT; VASCULARIZATION;

ADIPOSE TISSUE; ANGIOGENESIS INDUCING AGENTS; BIOLOGICAL MARKERS; GENE EXPRESSION; HUMANS; INSULIN RESISTANCE; METALLOPROTEASES; NEOVASCULARIZATION, PHYSIOLOGIC; OBESITY; OBESITY, MORBID; OMENTUM; SUBCUTANEOUS FAT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859138178     PISSN: None     EISSN: 14726793     Source Type: Journal    
DOI: 10.1186/1472-6793-12-4     Document Type: Article

References (35)

1. Metabolic implications of body fat distribution. Bjorntorp P, Diabetes Care 1991 14 1132 1143 10.2337/diacare.14.12.1132 1773700
2. All obese individuals are not created equal: insulin resistance is the major determinant of cardiovascular disease in overweight/obese individuals. Reaven G, Diab Vasc Dis Res 2005 2 105 112 10.3132/dvdr.2005.017 16334591 (Pubitemid 41695168)
3. Surgery for obesity. Colquitt JL, Picot J, Loveman E, Clegg AJ, Cochrane Database Syst Rev 2009 2 D003641 19370590
4. PPARgamma2 protects against obesity by means of a mechanism that mediates insulin resistance. Macias-Gonzalez M, Moreno-Santos I, García-Almeida JM, Tinahones FJ, Garcia-Fuentes E, Eur J Clin Invest 2009 39 11 972 979 10.1111/j.1365-2362.2009.02198.x 19645740
5. Abdominal obesity and metabolic syndrome. Despres JP, Lemieux I, Nature 2006 444 881 887 10.1038/nature05488 17167477 (Pubitemid 46024995)
6. The distinction of metabolically 'healthy' from 'unhealthy' obese individuals. Blüher M, Curr Opin Lipidol 2010 21 1 38 43 10.1097/MOL.0b013e3283346ccc 19915462
7. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Hanson RL, Imperatore G, Bennett PH, et al. Diabetes 2010 51 3120 3127
8. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Tan CY, Vidal-Puig A, Biochem Soc Trans 2008 36 Pt5 935 940 18793164
9. Obesity, inflammation, and atherosclerosis. Rocha VZ, Libby P, Nat Rev Cardiol 2009 6 6 399 409 10.1038/nrcardio.2009.55 19399028
10. Metabolic and body composition factors in subgroups of obesity: what do we know? Karelis AD, St-Pierre DH, Conus F, et al. J Clin Endocrinol Metab 2004 89 6 2569 2575 10.1210/jc.2004-0165 15181025 (Pubitemid 38766333)
11. Metabolic Syndrome and Insulin Resistance in Subjects with Morbid Obesity. Soverini V, Moscatiello S, Villanova N, et al. Obes Surg 2010 20 3 295 301 10.1007/s11695-009-9999-z 19841991
12. The Obese Without Cardiometabolic Risk Factor Clustering and the Normal Weight With Cardiometabolic Risk Factor Clustering Prevalence and Correlates of 2 Phenotypes Among the US Population (NHANES 1999-2004). Wildman RP, Muntner P, Reynolds K, et al. Arch Intern Med 2008 168 15 1617 1624 10.1001/archinte.168. 15.1617 18695075
13. Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Ledoux S, Queguiner I, Msika S, Calderari S, Rufat P, Gasc JM, Corvol P, Larger E, Diabetes 2008 57 12 3247 3257 10.2337/db07-1812 18835936
14. Role of proteolysis in development of murine adipose tissue. Christiaens V, Scroyen I, Lijnen HR, Thromb Haemost 2008 99 2 290 294 18278177 (Pubitemid 351230958)
15. Adipose tissue angiogenesis. Hausman GJ, Richardson RL, J Anim Sci 2004 82 3 925 934 15032451 (Pubitemid 38572359)
16. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Nature 1996 380 435 439 10.1038/380435a0 8602241 (Pubitemid 26102719)
17. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Proc Natl Acad Sci USA 1998 95 11709 11714 10.1073/pnas.95.20.11709 9751730 (Pubitemid 28460479)
18. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, EMBO J 1996 15 290 298 8617204 (Pubitemid 26029207)
19. V: Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova T, Nat Immunol 2004 5 74 80 10.1038/ni1013 14634646 (Pubitemid 38081471)
20. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Nat Med 2001 7 186 191 10.1038/84635 11175849 (Pubitemid 32148485)
21. Obesity and the regulation of energy balance. Spiegelman BM, Flier JS, Cell 2001 104 4 531 543 10.1016/S0092-8674(01)00240-9 11239410 (Pubitemid 32201948)
22. Cellular and molecular aspects of adipose tissue development. Ailhaud G, Grimaldi P, Négrel R, Annu Rev Nutr 1992 12 207 233 10.1146/annurev.nu. 12.070192.001231 1503804
23. A review of the microcirculation of adipose tissue: anatomic, metabolic, and angiogenic perspectives. Crandall DL, Hausman GJ, Kral JG, Microcirculation 1997 4 211 232 10.3109/10739689709146786 9219215 (Pubitemid 127674006)
24. Matrix metalloproteinases: effectors of development and normal physiology. Vu TH, Werb Z, Genes Dev 2000 14 17 2123 2133 10.1101/gad.815400 10970876
25. How matrix metalloproteinases regulate cell behavior. Sternlicht MD, Werb Z, Annu Rev Cell Dev Biol 2001 17 463 516 10.1146/annurev.cellbio.17.1.463 11687497 (Pubitemid 33096184)
26. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, et al. J Surg Res 1997 67 2 147 154 10.1006/jsre.1996.4983 9073561 (Pubitemid 27188010)
27. Modulation of angiogenesis during adipose tissue development in murine models of obesity. Voros G, Maquoi E, Demeulemeester D, Clerx N, Collen D, Lijnen HR, Endocrinology 2005 146 4545 4554 10.1210/en.2005-0532 16020476 (Pubitemid 41324053)
28. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, et al. J Clin Invest 2007 117 2621 2637 10.1172/JCI31021 17717599 (Pubitemid 47494363)
29. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B, EMBO J 1998 17 5085 5094 10.1093/emboj/17.17.5085 9724644 (Pubitemid 28408474)
30. Inflammation and insulin resistance. de Luca C, Olefsky JM, FEBS Lett 2008 582 97 105 10.1016/j.febslet.2007.11.057 18053812 (Pubitemid 50010731)
31. Obesity and free fatty acids. Boden G, Endocrinol Metab Clin North Am 2008 37 635 646 10.1016/j.ecl.2008.06.007 18775356
32. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. Roberts CK, Won D, Pruthi S, Kurtovic S, Sindhu RK, et al. J Appl Physiol 2006 100 1657 1665 10.1152/japplphysiol.01292.2005 16357066
33. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. Unal R, Yao-Borengasser A, Varma V, Rasouli N, Labbate C, et al. J Clin Endocrinol Metab 2010 95 2993 3001 10.1210/jc.2009-2623 20392866
34. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Bouloumie A, Sengenes C, Portolan G, Galitzky J, Lafontan M, Diabetes 2001 50 2080 2086 10.2337/diabetes.50.9.2080 11522674 (Pubitemid 33643675)
35. Matrix metalloproteinase-2 and -9 levels in obese patients. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, Cicero AF, Endothelium 2008 15 4 219 224 10.1080/10623320802228815 18663625